In 2017, 1,5-naphthyridines showed an optimal pharmacokinetic profile as potent and selective binders to human Alzheimer disease (AD) aggregated tau, which implies them as potential tau PET tracer binders [38]. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.